Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Dr. Reddy's Laboratories Limited    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mumbai Stock Exchange
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
4828.3 4910.95 4806.45 4898.8 4829.6 Last
74602 45681 80937 67637 34183 Volume
+3.37% +1.71% -2.13% +1.92% -1.41% Change
Financials
Sales 2021 193 B 2 608 M 2 608 M
Net income 2021 27 597 M 373 M 373 M
Net cash position 2021 10 068 M 136 M 136 M
P/E ratio 2021 29,2x
Yield 2021 0,53%
Sales 2022 216 B 2 923 M 2 923 M
Net income 2022 32 581 M 441 M 441 M
Net cash position 2022 29 623 M 401 M 401 M
P/E ratio 2022 24,7x
Yield 2022 0,59%
Capitalization 801 B 10 822 M 10 835 M
EV / Sales 2021 4,10x
EV / Sales 2022 3,57x
Nbr of Employees 21 650
Free-Float 68,2%
More Financials
Company
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products,... 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
All news about DR. REDDY'S LABORATORIES LIMITED
11:35aDR REDDY LABORATORIES : . Reddy's to Acquire Select Anti-Allergy Brands from Gle..
BU
11/27Pharma firm in India to make Russia's Sputnik V COVID-19 vaccine
RE
11/20DR REDDY LABORATORIES : Half yearly disclosure of related party transactions - S..
PU
11/17India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints
RE
11/16APPILI THERAPEUTICS : Reports Financial and Operational Results for Second Quart..
AQ
11/12DR REDDY LABORATORIES : Announces the Launch of Succinylcholine Chloride Injecti..
BU
11/12India's Serum says made 40 million doses of AstraZeneca's COVID vaccine, to m..
RE
11/09DR REDDY LABORATORIES : Presents Preclinical Data at SITC 2020 Demonstrating Sig..
BU
10/29DR REDDY LABORATORIES : Outcome of Board Meeting
PU
10/29DR REDDY LABORATORIES : . Reddy's partners with Department of Biotechnology - Bi..
BU
10/28DR REDDY LABORATORIES : India trials of Russian Sputnik-V vaccine may end as ear..
RE
10/28DR REDDY LABORATORIES : . Reddy's Names Parag Agarwal Chief Financial Officer
DJ
10/28DR REDDY LABORATORIES : Announces Appointment of New Chief Financial Officer
BU
10/28DOCTOR REDDY'S : Fiscal 2Q Earnings Snapshot
AQ
10/28DR REDDY LABORATORIES : . Reddy's Q2 & H1 FY21 Financial Results
BU
More news
News in other languages on DR. REDDY'S LABORATORIES LIMITED
05/15DR. REDDY'S LABORATORIES LIMITED : Veröffentlichung des Jahresergebnisses
05/15DR. REDDY'S LABORATORIES LIMITED : publication des résultats annuels
05/08DR. REDDY'S LABORATORIES LIMITED : Veröffentlichung des Jahresergebnisses
05/08DR. REDDY'S LABORATORIES LIMITED : publication des résultats annuels
2019INDIVIOR : paie cher sa dépendance au Subutex
More news
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 5 522,33 INR
Last Close Price 4 829,60 INR
Spread / Highest target 32,5%
Spread / Average Target 14,3%
Spread / Lowest Target -17,2%
EPS Revisions
Managers
NameTitle
Erez Israeli Chief Executive & Operating Officer
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors